BioPharma Digest

TL;DR: The FDA’s 2024 guidance officially supports virtual and hybrid clinical trials, allowing for telehealth visits and remote data collection. This aims to make trials more accessible and inclusive for both patients and healthcare providers.

In a major step toward modernizing medical research, the U.S. Food and Drug Administration (FDA) has released its final 2024 guidance on decentralized clinical trials (DCTs). This new framework reinforces the growing momentum behind virtual and hybrid trial models — an approach that makes studies more accessible to people who live far from research centers or face challenges attending in-person appointments. While these methods gained traction during the COVID-19 pandemic, the FDA’s guidance now formally supports them moving forward.

What Are Decentralized Clinical Trials?

Decentralized clinical trials allow some, or even all, parts of a study to happen outside of a traditional research facility. Instead of going to a hospital or clinic for every visit, participants might:

• Connect with the study team via video calls
• Receive study medications at home
• Use mobile apps or wearable devices to report symptoms and health data
• Have lab work done by a nurse visiting their home or a nearby clinic

These changes can ease the burden of participation, especially for people with demanding schedules, transportation issues, or health conditions that make travel difficult.

Some trials may be fully virtual, while others take a hybrid approach that blends in-person and remote elements.

What Does the FDA’s 2024 Guidance Say?

The document, Conducting Clinical Trials with Decentralized Elements, doesn’t create new rules, but it clarifies how existing regulations apply to remote or digital aspects of clinical trials. It provides detailed advice for researchers and sponsors to help them design safe, effective, and compliant decentralized studies.

Here are the key takeaways:

• Telehealth is supported: The FDA confirms that video visits, electronic health records, and remote monitoring tools are acceptable ways to collect study data.¹
• Flexibility is key: Researchers can tailor the level of decentralization to what’s appropriate for the treatment being tested.²
• Data quality and safety matter: Even in remote trials, patient privacy, informed consent, and the accuracy of collected data must be protected.
• Reduced red tape: The FDA has removed a requirement to name every local healthcare provider involved in a trial, lowering barriers for community-based providers to participate.³

The FDA is not introducing these ideas for the first time. Rather, the agency is recognizing that many organizations have already been using DCT methods. This guidance gives those practices a formal endorsement.

Why This Matters to Healthcare Professionals

Doctors, nurses, pharmacists, and other healthcare professionals may begin seeing more clinical trials reach into community settings. This creates new opportunities to:

• Help patients take part in trials without leaving their local care teams
• Refer patients to studies that don’t require long-distance travel
• Collaborate with researchers to collect meaningful, real-world data

These changes could transform how clinical trials operate. Healthcare providers may increasingly find themselves contributing to research efforts, from helping patients use digital tools to coordinating with trial sponsors. Understanding how DCTs work behind the scenes will allow providers to support patients more confidently and effectively.

What It Means for Patients and the Public

For patients, the move to decentralized trials means fewer barriers to participation. Traditional clinical trials often involve time-consuming travel and rigid schedules. In contrast, DCTs aim to bring the trial to the patient.

That means:

• A wider range of people, from rural areas to busy caregivers, can take part in research
• Patients can better integrate trial activities into their daily lives
• Study results may better reflect the needs and outcomes of diverse communities⁴

These improvements may help rebuild public trust in research by making it more inclusive and convenient.

What Challenges Remain?

While decentralized trials offer many benefits, they’re not a perfect solution. Barriers still exist, especially for people who don’t have internet access, smartphones, or the skills to use health apps confidently.

To address these challenges, researchers need to:

• Provide simple, easy-to-follow instructions for using trial technologies
• Ensure platforms are secure and comply with privacy regulations
• Offer tech support or alternatives for participants with low digital literacy

Without thoughtful planning, these gaps could lead to uneven participation and worsen existing health disparities.⁵

The Bottom Line

The FDA’s 2024 guidance doesn’t require trials to go virtual, but it just makes that option easier and more viable. For sponsors and researchers, it encourages innovation. For healthcare professionals, it opens new paths to integrate research with everyday patient care. And for patients, it’s a sign that clinical trials are evolving to be more convenient, inclusive, and patient-friendly.

References

1. U.S. Food and Drug Administration. Conducting Clinical Trials with Decentralized Elements: Guidance for Industry, Investigators, and Other Stakeholders. September 2024. Accessed May 2025. https://www.fda.gov/media/167882/download
2. Clinical Trials Transformation Initiative. Decentralized Clinical Trials. Accessed May 2025. https://www.ctti-clinicaltrials.org/projects/decentralized-clinical-trials
3. Medidata. FDA Finalizes Guidance on Decentralized Clinical Trials: What You Need to Know. 2024. Accessed May 2025. https://www.medidata.com/en/news/fda-finalizes-dct-guidance
4. Science 37. FDA’s Final DCT Guidance: A New Era for Clinical Research. 2024. Accessed May 2025. https://www.science37.com/resources
5. Izmailova ES, Ellis RJ, Benko C. Remote monitoring in clinical trials during the COVID-19 pandemic. Clin Transl Sci. 2021;14(5):1962-1969. doi:10.1111/cts.13057